RECRUITING

Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 2)

Talk to us

Conditions

SchizophreniaTranscranial magnetic stimulationwhite matterconnectivitymyelination

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil combined with cognitive training for improving white matter integrity.

Official Title

Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 2)

Quick Facts

Study Start:2025-04-16
Study Completion:2029-05-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06961916

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Male and female ages between ages 18-60 years
  2. 2. Ability to give written informed consent (age 18 or above)
  3. 3. Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above 10.
  1. 1. Inability to sign informed consent.
  2. 2. Any history of seizures.
  3. 3. Any acute and unstable major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but not limited to, recent stroke, seizure, history of significant head trauma, CNS infection or tumor, other significant brain neurological conditions (As this is a study of medical comorbidity, most medical conditions, once stable, are not exclusion criteria).
  4. 4. Taking \> 400 mg clozapine/day and not on anti-seizure medication(s) with sufficient dose.
  5. 5. Failed TMS screening questionnaire.
  6. 6. Significant alcohol or other drug use (substance abuse within 1 month or substance dependence history within 6 months and having substance usage within 1 month) other than nicotine or marijuana dependence.
  7. 7. A history of thrombosis, family history of thrombosis, or medical conditions that may lead to a hypercoagulable state (increased chance to develop blood clots)
  8. 8. Woman who is pregnant (child-bearing potential but not on contraceptive and missing menstrual period; or by self-report; or by positive urine pregnancy test).
  9. 9. History of head injury with loss of consciousness over 10 minutes; history of brain surgery
  10. 10. Cannot refrain from using alcohol and/or marijuana 24 hours or more prior to experiments.
  11. 11. Students and employees currently involved with our lab (lab employees and personnel will be excluded from the study to avoid possible coercion or possible appearance of coercion, or chance of breach of privacy and confidentiality).
  12. 12. For MRI, unable to undergo MRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips, or other implanted metal parts) or claustrophobic to the scanner.

Contacts and Locations

Study Contact

Bhim M Adhikari
CONTACT
713-486-2740
bhim.m.adhikari@uth.tmc.edu
Xiaoming Du, PhD
CONTACT
443-882-9717
Xiaoming.Du@uth.tmc.edu

Principal Investigator

Xiaoming Du, PhD
PRINCIPAL_INVESTIGATOR
The University of Texas Health Science Center, Houston

Study Locations (Sites)

The University of Texas Health Science Center, Houston
Houston, Texas, 77054
United States

Collaborators and Investigators

Sponsor: The University of Texas Health Science Center, Houston

  • Xiaoming Du, PhD, PRINCIPAL_INVESTIGATOR, The University of Texas Health Science Center, Houston

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-04-16
Study Completion Date2029-05-01

Study Record Updates

Study Start Date2025-04-16
Study Completion Date2029-05-01

Terms related to this study

Keywords Provided by Researchers

  • Transcranial magnetic stimulation
  • schizophrenia
  • white matter
  • connectivity
  • myelination

Additional Relevant MeSH Terms

  • Schizophrenia